L.J. Altfest & Co’s Viridian Therapeutics VRDN Stock Holding History

L.J. Altfest & Co’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,767	Closed	-$304K	–	381
2025 Q4	$304K	Sell	9,767 -3,783	-28%	-$104K	0.03%	283
2025 Q3	$292K	Buy	13,550 +340	+3%	+$6.13K	0.03%	291
2025 Q2	$185K	Buy	+13,210	New	+$179K	0.02%	324
2024 Q4	–	Sell	-13,512	Closed	-$307K	–	371
2024 Q3	$307K	Buy	+13,512	New	+$221K	0.04%	273

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

L.J. Altfest & Co's VRDN Position: Q1 2026 in Review

L.J. Altfest & Co sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 9,767 shares — an estimated $304K sold.

L.J. Altfest & Co first reported a position in VRDN in Q3 2024 and held it in 4 quarters. The position peaked at $307K in Q3 2024. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

L.J. Altfest & Co reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
L.J. Altfest & Co sold 9,767 Viridian Therapeutics shares in Q1 2026, an estimated $304K.
L.J. Altfest & Co first reported a position in Viridian Therapeutics in Q3 2024 and held it in 4 quarters.
L.J. Altfest & Co's Viridian Therapeutics position peaked at $307K in Q3 2024.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on L.J. Altfest & Co's 13F filing for Q1 2026, filed 28 Apr 2026.